261 related articles for article (PubMed ID: 37705003)
1. Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study.
Tsai CH; Chao CC; Hsieh ST; Yu AL; Wu YA; Cheng MF; Lee MJ; Chou CH; Shun CT; Hsueh HW; Jyh-Ming Juang J; Tseng PH; Su MY; Lin YH
Orphanet J Rare Dis; 2023 Sep; 18(1):289. PubMed ID: 37705003
[TBL] [Abstract][Full Text] [Related]
2. Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis.
Wu YA; Yu AL; Cheng MF; Lin LC; Lee MJ; Chou CH; Shun CT; Hsueh HW; Juang JJ; Tseng PH; Lin SP; Su MY; Chao CC; Hsieh ST; Tsai CH; Lin YH
Ther Adv Chronic Dis; 2024; 15():20406223231222828. PubMed ID: 38223905
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Tafamidis in Patients with Ala97Ser Hereditary Transthyretin Cardiac Amyloidosis: A Six-Month Follow-Up Study.
Tsai CH; Yu AL; Wu YA; Su MY; Cheng MF; Chou CH; Shun CT; Hsueh HW; Juang JJ; Lee MJ; Tseng PH; Hsieh ST; Chao CC; Lin YH
Acta Cardiol Sin; 2023 Jul; 39(4):619-627. PubMed ID: 37456942
[TBL] [Abstract][Full Text] [Related]
4. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.
Rettl R; Mann C; Duca F; Dachs TM; Binder C; Ligios LC; Schrutka L; Dalos D; Koschutnik M; Donà C; Kammerlander A; Beitzke D; Loewe C; Charwat-Resl S; Hengstenberg C; Kastner J; Eslam RB; Bonderman D
Eur Heart J Cardiovasc Imaging; 2022 Jun; 23(6):767-780. PubMed ID: 34788394
[TBL] [Abstract][Full Text] [Related]
5. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Shah SJ; Fine N; Garcia-Pavia P; Klein AL; Fernandes F; Weissman NJ; Maurer MS; Boman K; Gundapaneni B; Sultan MB; Elliott P
JAMA Cardiol; 2024 Jan; 9(1):25-34. PubMed ID: 37966817
[TBL] [Abstract][Full Text] [Related]
6. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
Rettl R; Wollenweber T; Duca F; Binder C; Cherouny B; Dachs TM; Camuz Ligios L; Schrutka L; Dalos D; Beitzke D; Loewe C; Badr Eslam R; Kastner J; Hacker M; Bonderman D
Eur Heart J Cardiovasc Imaging; 2023 Jul; 24(8):1019-1030. PubMed ID: 36881774
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.
Chamling B; Bietenbeck M; Korthals D; Drakos S; Vehof V; Stalling P; Meier C; Yilmaz A
Clin Res Cardiol; 2023 Mar; 112(3):353-362. PubMed ID: 35666277
[TBL] [Abstract][Full Text] [Related]
8. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
[TBL] [Abstract][Full Text] [Related]
10. Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis.
Giblin GT; Cuddy SAM; González-López E; Sewell A; Murphy A; Dorbala S; Falk RH
Eur Heart J Cardiovasc Imaging; 2022 Jul; 23(8):1029-1039. PubMed ID: 35274130
[TBL] [Abstract][Full Text] [Related]
11. Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy.
Dobner S; Bernhard B; Ninck L; Wieser M; Bakula A; Wahl A; Köchli V; Spano G; Boscolo Berto M; Elchinova E; Safarkhanlo Y; Stortecky S; Schütze J; Shiri I; Hunziker L; Gräni C
ESC Heart Fail; 2024 May; ():. PubMed ID: 38736040
[TBL] [Abstract][Full Text] [Related]
12. Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy.
Rettl R; Duca F; Binder C; Dachs TM; Cherouny B; Camuz Ligios L; Mann C; Schrutka L; Dalos D; Charwat-Resl S; Badr Eslam R; Kastner J; Bonderman D
Amyloid; 2023 Mar; 30(1):127-137. PubMed ID: 36251806
[TBL] [Abstract][Full Text] [Related]
13. Reverse cardiac remodelling and dysfunction in A97S transthyretin cardiac amyloidosis after tafamidis treatment.
Wu YA; Tsai CH; Su MY; Chao CC; Cheng MF; Shun CT; Hsieh ST; Lin YH
ESC Heart Fail; 2022 Dec; 9(6):4335-4339. PubMed ID: 36128649
[TBL] [Abstract][Full Text] [Related]
14. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
15. Cardiac MRI T1 and T2 Mapping as a Quantitative Imaging Biomarker in Transthyretin Amyloid Cardiomyopathy.
Yamaguchi S; Oda S; Kidoh M; Hayashi H; Takashio S; Usuku H; Nagayama Y; Nakaura T; Tsujita K; Hirai T; Aoki T
Acad Radiol; 2024 Feb; 31(2):514-522. PubMed ID: 37775448
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
[TBL] [Abstract][Full Text] [Related]
17. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy.
Takashio S; Morioka M; Ishii M; Morikawa K; Hirakawa K; Hanatani S; Oike F; Usuku H; Kidoh M; Oda S; Yamamoto E; Matsushita K; Ueda M; Tsujita K
ESC Heart Fail; 2023 Aug; 10(4):2319-2329. PubMed ID: 37073415
[TBL] [Abstract][Full Text] [Related]
19. Impact of Tafamidis on Echocardiographic Cardiac Function of Patients With Transthyretin Cardiac Amyloidosis.
Ichikawa Y; Oota E; Odajima S; Kintsu M; Todo S; Takeuchi K; Yamauchi Y; Shiraki H; Yamashita K; Fukuda T; Hisamatsu E; Hirata KI; Tanaka H
Circ J; 2023 Mar; 87(4):508-516. PubMed ID: 36878601
[TBL] [Abstract][Full Text] [Related]
20. Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study.
Garcia-Pavia P; Sultan MB; Gundapaneni B; Sekijima Y; Perfetto F; Hanna M; Witteles R
JACC Heart Fail; 2024 Jan; 12(1):150-160. PubMed ID: 37943223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
